Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan G Duda

Showing results (151-160 of 261) with videos related to

Pageof 27
Sort By:
Nature Clinical Practice. Oncology|December 2, 2006
Platelet-derived growth factor receptor-beta in Gorham's diseaseJeroen Hagendoorn, Timothy P Padera, Torunn I Yock, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 10, 2025
A prospective study of immune responses in patients with lung metastases treated with stereotactic body radiotherapy with or without concurrent systemic treatmentEleni Gkika, Elke Firat, Sonja Adebahr, et al.
Journal of Hepatocellular Carcinoma|March 11, 2024
Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular CarcinomaShadi Chamseddine, Michael LaPelusa, Lianchun Xiao, et al.
Cancer Research|June 25, 2009
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patientsA Gregory Sorensen, Tracy T Batchelor, Wei-Ting Zhang, et al.
Molecular Cancer|August 2, 2024
Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancerPrashant Dogra, Vrushaly Shinglot, Javier Ruiz-Ramírez, et al.
Medrxiv : the Preprint Server for Health Sciences|April 1, 2024
Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancerPrashant Dogra, Vrushaly Shinglot, Javier Ruiz-Ramírez, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 22, 2015
Quantum dot/antibody conjugates for in vivo cytometric imaging in miceHee-Sun Han, Elisabeth Niemeyer, Yuhui Huang, et al.
Surgical Oncology|October 1, 2025
A tumor microenvironment-based classification of gastric cancer for more effective diagnosis and treatmentSimona O Dima, Andrei Sorop, Shuji Kitahara, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 2, 2016
A protein and mRNA expression-based classification of gastric cancerNamrata Setia, Agoston T Agoston, Hye S Han, et al.
Neuro-Oncology|May 27, 2015
A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastomaElizabeth R Gerstner, Xiaobu Ye, Dan G Duda, et al.
Pageof 27

Showing results (151-160 of 261) with videos related to

Sort By:
Pageof 27
Nature Clinical Practice. Oncology|December 2, 2006
Platelet-derived growth factor receptor-beta in Gorham's diseaseJeroen Hagendoorn, Timothy P Padera, Torunn I Yock, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 10, 2025
A prospective study of immune responses in patients with lung metastases treated with stereotactic body radiotherapy with or without concurrent systemic treatmentEleni Gkika, Elke Firat, Sonja Adebahr, et al.
Journal of Hepatocellular Carcinoma|March 11, 2024
Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular CarcinomaShadi Chamseddine, Michael LaPelusa, Lianchun Xiao, et al.
Cancer Research|June 25, 2009
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patientsA Gregory Sorensen, Tracy T Batchelor, Wei-Ting Zhang, et al.
Molecular Cancer|August 2, 2024
Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancerPrashant Dogra, Vrushaly Shinglot, Javier Ruiz-Ramírez, et al.
Medrxiv : the Preprint Server for Health Sciences|April 1, 2024
Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancerPrashant Dogra, Vrushaly Shinglot, Javier Ruiz-Ramírez, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 22, 2015
Quantum dot/antibody conjugates for in vivo cytometric imaging in miceHee-Sun Han, Elisabeth Niemeyer, Yuhui Huang, et al.
Surgical Oncology|October 1, 2025
A tumor microenvironment-based classification of gastric cancer for more effective diagnosis and treatmentSimona O Dima, Andrei Sorop, Shuji Kitahara, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 2, 2016
A protein and mRNA expression-based classification of gastric cancerNamrata Setia, Agoston T Agoston, Hye S Han, et al.
Neuro-Oncology|May 27, 2015
A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastomaElizabeth R Gerstner, Xiaobu Ye, Dan G Duda, et al.
Pageof 27